Catyalyst Pharma (CPRX) Reports In-Line Q4 EPS
Catyalyst Pharma (NASDAQ: CPRX) reported Q4 EPS of ($0.06), in-line with the analyst estimate of ($0.06).
For earnings history and earnings-related data on Catyalyst Pharma (CPRX) click here.
Catyalyst Pharma (NASDAQ: CPRX) reported Q4 EPS of ($0.06), in-line with the analyst estimate of ($0.06).
For earnings history and earnings-related data on Catyalyst Pharma (CPRX) click here.